Explore the latest in esophageal cancer, including advances in understanding the epidemiology, diagnosis, management, and prevention of the disease.
This JAMA Patient Page explains the role of esophageal surgery in the management of esophageal cancer and the differences between minimally invasive (laparoscopic and robotic) vs open approaches.
This randomized clinical trial assesses the efficacy and toxicity of radiotherapy plus icotinib compared with radiotherapy alone in older patients with unresectable esophageal squamous cell carcinoma (ESCC) in China.
This cohort study assesses whether chemoradiotherapy is associated with thoracic vertebral fractures in patients with esophageal cancer.
This cohort study examines national rates of neoadjuvant dual-agent chemotherapy and radiation followed by surgery in patients with locally advanced esophageal carcinoma after a randomized clinical trial demonstrated a survival advantage.
This phase 2 nonrandomized clinical trial evaluates the clinical activity and safety of the FOLFIRINOX regimen (leucovorin, fluorouracil, irinotecan, and oxaliplatin) as first-line treatment for patients with advanced gastroesophageal adenocarcinoma.
This case series describes intratumoral spatial heterogeneity of tumor cell populations and investigates its association with survival among patients with nonmetastatic gastroesophageal adenocarcinoma.
This phase 2 trial evaluates the coprimary end points of margin-negative (R0) resection rates and pathologic response grades of gFOLFIRINOX (fluorouracil, leucovorin, oxaliplatin, and UGT1A1 genotype-directed irinotecan) therapy among patients with locally advanced gastroesophageal adenocarcinoma.
This case-control study examines whether high-risk human papillomavirus–related biomarkers are associated with survival among adult patients with Barrett high-grade dysplasia and esophageal adenocarcinoma.
This subgroup analysis of a randomized clinical trial compares trifluridine/tipiracil treatment with placebo for progression-free and overall survival among patients with previously treated metastatic gastric or gastroesophageal junction cancer who had or had not undergone gastrectomy.
This diagnostic study describes a novel attention-based deep neural network framework for classifying microscopy images to identify Barrett esophagus and esophageal adenocarcinoma.
This phase 1/2 single-arm trial examined toxic effects, local control, and overall survival rates after chemoradiotherapy with a simultaneous integrated boost of radiotherapy dose to the gross tumor and nodal disease for patients with unresectable locally advanced esophageal cancer.
This randomized clinical trial investigates the efficacy and safety of adding ramucirumab to first-line therapy with S-1 and oxaliplatin among East Asian adults with advanced gastric cancer.
This phase 2 randomized clinical trial investigates the effects of adding lapatinib to perioperative epirubicin, cisplatin, and capecitabine chemotherapy in patients with potentially curable HER2-positive gastroesophageal adenocarcinoma.
This cohort study evaluates the association of serological biomarkers with the response to immune checkpoint blockade therapy in patients with metastatic gastrointestinal tract cancer.
This case-control study establishes and assesses the validity of a model using serum microRNAs (miRNAs) to distinguish patients with esophageal squamous cell carcinoma (SCC) from patients without cancer.
This phase 2, open-label, interventional study examined the safety and efficacy of pembrolizumab for patients with advanced, metastatic esophageal carcinoma that has progressed after 2 or more lines of systemic therapy.
This study assesses the prevalence of false-negative results and the accuracy of intraoperative consultations on surgical margins in patients undergoing curative intent resection for gastric or gastroesophageal adenocarcinoma.
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: